Felicitas La Rosée
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Felicitas La Rosée has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Paul La Rosée
Klinik für Innere Medizin II, Schwarzwald-Baar Klinikum, Villingen-Schwenningen, Germany
5 shared publications A. Hochhaus
Klinik für Innere Medizin II, Universitätsklinikum Jena, Friedrich-Schiller-Universität Jena, Jena, Germany
2 shared publicationsJ. Hammersen
Universitätsklinikum Jena, Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie, Jena, Germany
2 shared publications- Philipp Alexander Reuken
Jena University Hospital
2 shared publications - Sebastian Birndt
Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany
2 shared publications A. Kehr
Klinik für Innere Medizin IV, Schwarzwald-Baar-Klinikum, Villingen-Schwenningen, Germany
1 shared publication
Latest Publications
- 28 November 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (22) , 2274-2275
HLH: diagnostics revisited and improved
- 28 November 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (22) , 2274-2275
HLH: diagnostics revisited and improved
- Open Access
- 28 July 2023
- Published by Springer Nature in Leukemia
- Vol. 37 (9) , 1879-1886
The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial
Dysregulated hyperinflammatory response is key in the pathogenesis in patients with severe COVID-19 leading to acute respiratory distress syndrome and multiorgan failure. Whilst immunosuppression has been proven to be effective, potential biological targets and optimal timing of treatment are still conflicting. We sought to evaluate efficacy and safety of the Janus Kinase 1/2 inhibitor ruxolitinib, employing the previously developed COVID-19 Inflammation Score (CIS) in a prospective multicenter open label phase II trial (NCT04338958). Primary objective was reversal of hyperinflammation (CIS reduction of ≥25% at day 7 in ≥20% of patients). In 184 patients with a CIS of ≥10 (median 12) ruxolitinib was commenced at an initial dose of 10 mg twice daily and applied over a median of 14 days (range, 2–31). On day 7, median CIS declined to 6 (range, 1–13); 71% of patients (CI 64–77%) achieved a ≥25% CIS reduction accompanied by a reduction of markers of inflammation. Median cumulative dose was 272.5 mg/d. Treatment was well tolerated without any grade 3–5 adverse events related to ruxolitinib. Forty-four patients (23.9%) died, all without reported association to study drug. In conclusion, ruxolitinib proved to be safe and effective in a cohort of COVID-19 patients with defined hyperinflammation.
- 28 July 2023
- Published by Springer Nature in Leukemia
- Vol. 37 (9) , 1879-1886
Open AccessThe JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial
Dysregulated hyperinflammatory response is key in the pathogenesis in patients with severe COVID-19 leading to acute respiratory distress syndrome and multiorgan failure. Whilst immunosuppression has been proven to be effective, potential biological targets and optimal timing of treatment are still conflicting. We sought to evaluate efficacy and safety of the Janus Kinase 1/2 inhibitor ruxolitinib, employing the previously developed COVID-19 Inflammation Score (CIS) in a prospective multicenter open label phase II trial (NCT04338958). Primary objective was reversal of hyperinflammation (CIS reduction of ≥25% at day 7 in ≥20% of patients). In 184 patients with a CIS of ≥10 (median 12) ruxolitinib was commenced at an initial dose of 10 mg twice daily and applied over a median of 14 days (range, 2–31). On day 7, median CIS declined to 6 (range, 1–13); 71% of patients (CI 64–77%) achieved a ≥25% CIS reduction accompanied by a reduction of markers of inflammation. Median cumulative dose was 272.5 mg/d. Treatment was well tolerated without any grade 3–5 adverse events related to ruxolitinib. Forty-four patients (23.9%) died, all without reported association to study drug. In conclusion, ruxolitinib proved to be safe and effective in a cohort of COVID-19 patients with defined hyperinflammation.
- Open Access
- 7 September 2021
- Published by Springer Nature in Leukemia
- Vol. 35 (12) , 3613-3615
The impact of specific cytokine directed treatment on severe COVID-19
- 7 September 2021
- Published by Springer Nature in Leukemia
- Vol. 35 (12) , 3613-3615
Open AccessThe impact of specific cytokine directed treatment on severe COVID-19
- 20 August 2020
- Published by S. Karger AG in Acta Haematologica
- Vol. 144 (3) , 246-249
Ruxolitinib in COVID-19 Hyperinflammation and Haematologic Malignancies
COVID-19 is a pandemic illness forcing clinicians and clinician scientists to respond to an unforeseen 20% rate of hospital admissions due to respiratory distress and a sepsis-like hyperinflammatory cytokine release syndrome that develops in a subgroup of SARS-CoV2-infected patients. Initial results of the WUHAN COVID-19 cohort suggested a major impact of hyperinflammation characterized by a specific cytokine profile including IL-1β, IL-6, and TNF-α on patient outcome. Lessons learned from the novel coronavirus outbreak combined with knowledge that accumulated after the first SARS epidemic have revealed a biphasic pulmonary immune response. The majority of individuals recover after an initial virus-clearing IFN-I response. Yet, with “false fine-tuning” regulated by host and environmental factors, the immune-response can accelerate to a second cytokine wave leading to recruitment of lymphocytes and macrophages to the lung which in turn governs the development of acute respiratory distress syndrome (ARDS) and progressive hyperferritinemic hyperinflammation. Rarely but dangerously, this culminates in macrophage activation syndrome (MAS) like sepsis with multiorgan failure. The antiviral drug remdesivir (rem) applied at early stages and the corticosteroid dexamethasone (dex) in oxygen-dependent and severely affected patients by now seem the only disease-modifying agents with signals of efficacy in randomized controlled trials [1]. Rem seems to shorten recovery time, whereas dex impacts overall survival particularly in ARDS. The British recovery trial demonstrating dex superiority over SOC supports the hypothesis that 6 mg of dex for 10 days helps to reverse pulmonary failure without putting patients on risk for secondary infections and delayed viral clearance. Due to red flags put in place by the WHO and national medical societies regarding potentially detrimental steroid effects and the early data on cytokine release syndrome (CRS), a variety of compassionate use, targeted cytokine directed drugs have been reported in single case reports or case series, which were hypothesis-generating for prospective clinical trials. As of August 1, 2020, the majority of reported cases involve IL-6R blocking tocilizumab, IL-1R blocking anakinra, and the multiple cytokines blocking JAK1/2 inhibitor baricitinib. The recently published series on the JAK/STAT inhibitor ruxolitinib (rux) add another smart drug to the armamentarium against an array of inflammatory cytokines [2, 3]. Rux is approved for treatment of the myeloproliferative neoplasias polycythaemia vera and primary or secondary myelofibrosis as well as FDA-approved for glucocorticoid-refractory graft-versus-host disease. It also shows convincing efficacy in refractory secondary hemophagocytic lymphohistiocytosis (sHLH), another subtype of hyperferritinemic inflammation syndromes.
- 20 August 2020
- Published by S. Karger AG in Acta Haematologica
- Vol. 144 (3) , 246-249
Ruxolitinib in COVID-19 Hyperinflammation and Haematologic Malignancies
COVID-19 is a pandemic illness forcing clinicians and clinician scientists to respond to an unforeseen 20% rate of hospital admissions due to respiratory distress and a sepsis-like hyperinflammatory cytokine release syndrome that develops in a subgroup of SARS-CoV2-infected patients. Initial results of the WUHAN COVID-19 cohort suggested a major impact of hyperinflammation characterized by a specific cytokine profile including IL-1β, IL-6, and TNF-α on patient outcome. Lessons learned from the novel coronavirus outbreak combined with knowledge that accumulated after the first SARS epidemic have revealed a biphasic pulmonary immune response. The majority of individuals recover after an initial virus-clearing IFN-I response. Yet, with “false fine-tuning” regulated by host and environmental factors, the immune-response can accelerate to a second cytokine wave leading to recruitment of lymphocytes and macrophages to the lung which in turn governs the development of acute respiratory distress syndrome (ARDS) and progressive hyperferritinemic hyperinflammation. Rarely but dangerously, this culminates in macrophage activation syndrome (MAS) like sepsis with multiorgan failure. The antiviral drug remdesivir (rem) applied at early stages and the corticosteroid dexamethasone (dex) in oxygen-dependent and severely affected patients by now seem the only disease-modifying agents with signals of efficacy in randomized controlled trials [1]. Rem seems to shorten recovery time, whereas dex impacts overall survival particularly in ARDS. The British recovery trial demonstrating dex superiority over SOC supports the hypothesis that 6 mg of dex for 10 days helps to reverse pulmonary failure without putting patients on risk for secondary infections and delayed viral clearance. Due to red flags put in place by the WHO and national medical societies regarding potentially detrimental steroid effects and the early data on cytokine release syndrome (CRS), a variety of compassionate use, targeted cytokine directed drugs have been reported in single case reports or case series, which were hypothesis-generating for prospective clinical trials. As of August 1, 2020, the majority of reported cases involve IL-6R blocking tocilizumab, IL-1R blocking anakinra, and the multiple cytokines blocking JAK1/2 inhibitor baricitinib. The recently published series on the JAK/STAT inhibitor ruxolitinib (rux) add another smart drug to the armamentarium against an array of inflammatory cytokines [2, 3]. Rux is approved for treatment of the myeloproliferative neoplasias polycythaemia vera and primary or secondary myelofibrosis as well as FDA-approved for glucocorticoid-refractory graft-versus-host disease. It also shows convincing efficacy in refractory secondary hemophagocytic lymphohistiocytosis (sHLH), another subtype of hyperferritinemic inflammation syndromes.
- Top Cited PapersOpen Access
- 9 June 2020
- Published by Springer Nature in Leukemia
- Vol. 34 (7) , 1805-1815
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
A subgroup of patients with severe COVID-19 suffers from progression to acute respiratory distress syndrome and multiorgan failure. These patients present with progressive hyperinflammation governed by proinflammatory cytokines. An interdisciplinary COVID-19 work flow was established to detect patients with imminent or full blown hyperinflammation. Using a newly developed COVID-19 Inflammation Score (CIS), patients were prospectively stratified for targeted inhibition of cytokine signalling by the Janus Kinase 1/2 inhibitor ruxolitinib (Rux). Patients were treated with efficacy/toxicity guided step up dosing up to 14 days. Retrospective analysis of CIS reduction and clinical outcome was performed. Out of 105 patients treated between March 30th and April 15th, 2020, 14 patients with a CIS ≥ 10 out of 16 points received Rux over a median of 9 days with a median cumulative dose of 135 mg. A total of 12/14 patients achieved significant reduction of CIS by ≥25% on day 7 with sustained clinical improvement in 11/14 patients without short term red flag warnings of Rux-induced toxicity. Rux treatment for COVID-19 in patients with hyperinflammation is shown to be safe with signals of efficacy in this pilot case series for CRS-intervention to prevent or overcome multiorgan failure. A multicenter phase-II clinical trial has been initiated (NCT04338958).
- 9 June 2020
- Published by Springer Nature in Leukemia
- Vol. 34 (7) , 1805-1815
Top Cited PapersOpen AccessThe Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
A subgroup of patients with severe COVID-19 suffers from progression to acute respiratory distress syndrome and multiorgan failure. These patients present with progressive hyperinflammation governed by proinflammatory cytokines. An interdisciplinary COVID-19 work flow was established to detect patients with imminent or full blown hyperinflammation. Using a newly developed COVID-19 Inflammation Score (CIS), patients were prospectively stratified for targeted inhibition of cytokine signalling by the Janus Kinase 1/2 inhibitor ruxolitinib (Rux). Patients were treated with efficacy/toxicity guided step up dosing up to 14 days. Retrospective analysis of CIS reduction and clinical outcome was performed. Out of 105 patients treated between March 30th and April 15th, 2020, 14 patients with a CIS ≥ 10 out of 16 points received Rux over a median of 9 days with a median cumulative dose of 135 mg. A total of 12/14 patients achieved significant reduction of CIS by ≥25% on day 7 with sustained clinical improvement in 11/14 patients without short term red flag warnings of Rux-induced toxicity. Rux treatment for COVID-19 in patients with hyperinflammation is shown to be safe with signals of efficacy in this pilot case series for CRS-intervention to prevent or overcome multiorgan failure. A multicenter phase-II clinical trial has been initiated (NCT04338958).